Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of chimeric polynucleotide molecules, which allow for customized placement, position and percent load of chemical modifications, which improve, alter or optimize certain physicochemical and pharmaceutical properties of the polynucleotides. In one non-limiting embodiment, such chimeric polynucleotides take the form or function as modified mRNA molecules which encode a polypeptide of interest. In one embodiment, such chimeric polynucleotides are substantially noncoding.

Abstract: The invention relates to compositions and methods for the preparation, manufacture and therapeutic use of circular polynucleotides.

Abstract: Aptamers for topical delivery and methods for topical use of aptamers are described. Aptamers that bind to interleukin (IL)-23 (IL-23 aptamers) and methods of using such aptamers are also described.

Abstract: The present invention relates to a cocrystal of progesterone and a coformer selected from the group consisting of vanillic acid, benzoic acid, salicylic acid, cinnamic acid, and vanillin. The present invention also relates to a pharmaceutical composition comprising a cocrystal of the present invention and at least one pharmaceutically acceptable carrier. The present invention further relates to a method of supplementing progesterone in women. This method involves administering to a female subject in need thereof a pharmaceutical composition of the present invention.

Abstract: A primary battery includes a cathode having an alkali-deficient nickel oxide including metals such as Ca, Mg, Al, Co, Y, Mn, and/or non-metals such as B, Si, Ge, or a combination of metal and/or non-metal atoms; a combination of metal atoms; an anode; a separator between the cathode and the anode; and an alkaline electrolyte.

Abstract: Disclosed herein are cocrystals of progesterone and a coformer containing a six-membered aromatic ring having at least one substituent possessing a carbonyl functionality. Cocrystals of progesterone and a coformer selected from vanillic acid, benzoic acid, salicylic acid, cinnamic acid, or vanillin are also disclosed herein.

Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.

Abstract: Methods of making high-energy cathode active materials for primary alkaline batteries are described. The primary batteries include a cathode having an alkali-deficient nickel(IV)-containing oxide including one or more metals such as Co, Mg, Al, Ca, Y, Mn, and/or non-metals such as B, Si, Ge or a combination of metal and/or non-metal atoms as dopants partially substituted for Ni and/or Li in the crystal lattice; an anode; a separator between the cathode and the anode; and an alkaline electrolyte solution.

Abstract: Disclosed herein are cocrystals of progesterone and a coformer containing a six-membered aromatic ring having at least one substituent possessing a carbonyl functionality. Cocrystals of progesterone and a coformer selected from vanillic acid, benzoic acid, salicylic acid, cinnamic acid, or vanillin are also disclosed herein.

Abstract: A primary alkaline battery includes a cathode having an alkali-deficient nickel (IV)-containing oxide including metals such as Ni, Co, Mg, Al, Ca, Y, Mn, and/or non-metals such as B, Si, Ge or a combination of metal and/or non-metal ions as stabilizing dopants; a combination of metal ions as dopants; an anode; a separator between the cathode and the anode; and an alkaline electrolyte. The battery can be pre-discharged within one hour after assembly to decrease the open circuit voltage.

Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.

Abstract: A primary alkaline battery includes a cathode having an alkali-deficient nickel (IV)-containing oxide including metals such as Ni, Co, Mg, Al, Ca, Y, Mn, and/or non-metals such as B, Si, Ge or a combination of metal and/or non-metal ions as stabilizing dopants; a combination of metal ions as dopants; an anode; a separator between the cathode and the anode; and an alkaline electrolyte. The battery can be pre-discharged within one hour after assembly to decrease the open circuit voltage.

Abstract: A primary battery includes a cathode having an alkali-deficient nickel oxide including metals such as Ca, Mg, Al, Co, Y, Mn, and/or non-metals such as B, Si, Ge, or a combination of metal and/or non-metal atoms; a combination of metal atoms; an anode; a separator between the cathode and the anode; and an alkaline electrolyte.

Abstract: Methods of making high-energy cathode active materials for primary alkaline batteries are described. The primary batteries include a cathode having an alkali-deficient nickel(IV)-containing oxide including one or more metals such as Co, Mg, Al, Ca, Y, Mn, and/or non-metals such as B, Si, Ge or a combination of metal and/or non-metal atoms as dopants partially substituted for Ni and/or Li in the crystal lattice; an anode; a separator between the cathode and the anode; and an alkaline electrolyte solution.

Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.

Abstract: A primary battery includes a cathode having an acid-treated manganese dioxide, an anode, a separator between the cathode and the anode, and an alkaline electrolyte.

Abstract: A primary battery includes a cathode having a non-stoichiometric metal oxide including transition metals Ni, Mn, Co, or a combination of metal atoms, an alkali metal, and hydrogen; an anode; a separator between the cathode and the anode; and an alkaline electrolyte.

Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.

Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.

Abstract: The invention relates generally to the field of nucleic acids and more particularly to aptamers that bind to TFPI, which are useful as therapeutics in and diagnostics of bleeding disorders and/or other diseases or disorders in which TFPI has been implicated. In addition, the TFPI aptamers may be used before, during and/or after medical procedures to reduce complications or side effects thereof. The invention further relates to materials and methods for the administration of aptamers that bind to TFPI.